Alaunos Therapeutics (TCRT) Other Operating Expenses (2009 - 2023)

Alaunos Therapeutics has reported Other Operating Expenses for 8 years, with the latest figure at $3.7 million in Q4 2023.

• For the quarter ending Q4 2023, Other Operating Expenses changed N/A year-over-year to $3.7 million; the trailing twelve-month figure through Sep 2024 stood at $3.7 million (up 388.12% YoY), and the FY2023 full-year result was $4.5 million, up 3487.22% from the prior year.
• Other Operating Expenses for Q4 2023 stood at $3.7 million, up from $1.0 million in the prior quarter.
• The five-year high for Other Operating Expenses was $3.7 million in Q4 2023, with the low at -$245000.0 in Q2 2023.
• Historically, Other Operating Expenses has averaged $1.0 million across 3 years, with a median of $740000.0 in 2021.
• The largest YoY upside for Other Operating Expenses was 84.21% in 2023 against a maximum downside of 84.21% in 2023.
• Alaunos Therapeutics' Other Operating Expenses stood at $740000.0 in 2021, then tumbled by 117.97% to -$133000.0 in 2022, then soared by 2911.28% to $3.7 million in 2023.
• The last three Other Operating Expenses figures came in at $3.7 million (Q4 2023), $1.0 million (Q3 2023), and -$245000.0 (Q2 2023), per Business Quant data.